EP2470015B1 - Nitrone derivate zur behandlung von schallempfindungsschwerhörigkeit - Google Patents

Nitrone derivate zur behandlung von schallempfindungsschwerhörigkeit Download PDF

Info

Publication number
EP2470015B1
EP2470015B1 EP10814226.6A EP10814226A EP2470015B1 EP 2470015 B1 EP2470015 B1 EP 2470015B1 EP 10814226 A EP10814226 A EP 10814226A EP 2470015 B1 EP2470015 B1 EP 2470015B1
Authority
EP
European Patent Office
Prior art keywords
composition
hearing loss
disulfonyl
aat
nac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10814226.6A
Other languages
English (en)
French (fr)
Other versions
EP2470015A1 (de
EP2470015A4 (de
Inventor
Richard Dana Kopke
Robert A. Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Hough Ear Institute
Original Assignee
Oklahoma Medical Research Foundation
Hough Ear Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, Hough Ear Institute filed Critical Oklahoma Medical Research Foundation
Publication of EP2470015A1 publication Critical patent/EP2470015A1/de
Publication of EP2470015A4 publication Critical patent/EP2470015A4/de
Application granted granted Critical
Publication of EP2470015B1 publication Critical patent/EP2470015B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • AAT Acute acoustic trauma
  • SNHL sensorineural hearing loss
  • the current invention provides a composition for treating hearing loss.
  • a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone is particularly useful for treating AAT-induced hearing loss.
  • the current invention provides a composition for treating hearing loss.
  • a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone and N-acetylcysteine is particularly useful for treating AAT-induced hearing loss.
  • the present invention is directed to a for treating AAT-induced hearing loss by orally administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone and N-acetyleysteine (NAC).
  • a composition comprising 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone and N-acetyleysteine (NAC).
  • the current invention provides a composition suitable for treating hearing loss resulting from oxidative stress such as may be induced by AAT.
  • the composition comprises a pharmaceutically effective amount of 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone.
  • the composition is suitable for oral administration to a patient.
  • the current invention provides a composition suitable for treating hearing loss resulting from oxidative stress such as may be induced by AAT.
  • the composition comprises pharmaceutically effective amounts of 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone and N-acetylcysteine.
  • the composition is suitable for oral administration to a patient.
  • the current invention provides a composition comprising 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone and N-acetylcysteine.
  • the individual components of this composition may be at less than pharmaceutically effective amounts yet the combination thereof is pharmaceutically effective for treating sensorineural hearing loss.
  • This invention provides for treating sensorineural hearing loss resulting from AAT and likely other causes of deafness related to oxidative stress, programmed cell death, or inflammatory processes.
  • Other causes of SNHL include age related hearing loss or presbyacusis, toxin-induced hearing loss, trauma induced hearing loss, viral or bacterial infection leading to hearing loss, hearing loss due to prematurity, hearing loss due to cochlear ischemia, congenital hearing loss, genetic hearing loss, Meniere's disease, sudden hearing loss, and hearing loss related to thyroid disorders or diabetes mellitus.
  • the current invention demonstrates the functionality of 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone as a free radical trap and the synergistic effect of combining the 2,4-disulfonyl ⁇ -phenyl tertiary butyl nitrone with N-acetylcysteine (NAC) in the treatment of AAT.
  • NAC N-acetylcysteine
  • 2,4-disulfanyl ⁇ -phenyl tertiary butyl nitrone will be referred to as 2,4-disulfonyl PBN or HPN-07.
  • the 2,4-disulfonyl PBN has the following stricture:
  • the acid form of the compound has the following structure:
  • the acid form may be a solid or found in low pH solutions.
  • the ionized salt form of the compound exists at higher pH and may be represented by either of the following structures: or In the salt form, X is a pharmaceutically acceptable cation.
  • this cation is a monovalent material such as sodium, potassium or ammonium, but it can also be a multivalent alone or cation in combination with a pharmaceutically acceptable monovalent anion, for example calcium with a chloride, bromide, iodide, hydroxyl, nitrate, sulfonate, acetate, tartrate, oxalate, succinate, palmoate or the like anion; magnesium with such anions; zinc with such anions or the like.
  • the free acid and the simple sodium, potassium or ammonium salts are most preferred with the calcium and magnesium salts also being preferred but somewhat less so.
  • the 2,4-disulfonyl PBN compound is described in detail by U.S. Patent No. 5,488,145 .
  • the salts of 2,4-disulfonyl PBN may also be used for the treatment of AAT in a manner similar to the use of 2,4-disulfonyl PBN as discussed below.
  • antioxidant peptides which target the mitochondria, are useful in the present invention and may be included as part of the composition for treating AAT. These compounds preclude the generation of intracellular reactive oxygen species (ROS) which leads to oxidative stress and damage of the mitochondria. Oxidative damage of the mitochondria is known to cause apoptosis and necrosis leading to cell death.
  • the preferred antioxidant peptides are Szeto-Schiller (SS) peptides and their functional analogs. These compounds have alternating aromatic residues and basic amino acids.
  • peptides having tyrosine (Tyr) or dimethyltyrosine (Dmt) analogs can scavenge oxyradicals. These compounds inhibit oxidation of low-density lipoproteins.
  • SS-peptides include compounds such as SS-31 (D-Arg-Dmt-Lys-Phe-NH 2 ) and SS-02 (Dmt-D-Arg-Phe-Lys-NH 2 ).
  • tryptophan containing SS-peptides are also useful in the current invention.
  • the amino acids found in the SS-peptides may be L or D and may be naturally occuring, non-naturally occuring and derivatives of naturally occuring amino acids.
  • the SS-peptides disclosed in PCT published application WO 2005/072295 are suitable for use in the current invention.
  • the current invention provides methods and compositions suitable for treating the referenced hearing conditions.
  • the current invention utilizes 2,4-disulfonyl PBN and N-acetylcysteine to treat AAT.
  • the composition of the current invention may optionally include additional antioxidant componds including, but not limited to, Acetyl-L-Carnitine (ALCAR), glutathione monoethylester, ebselen, D-methionine.
  • compositions of the current invention will preferably be administered orally; however, other delivery methods including, but not limited to, intravenously, subcutaneously, by inhalation, sublingually, subdermally or locally within the ear are also suitable.
  • the active composition may be administered as a nanoparticle or dendrimer formulation.
  • the nanoparticle may be multifunctional and composed of a polymer and paramagnetic iron oxide particles to allow the application of external magnetic forces to aid in the delivery of the drug to the desired target such as the inner ear.
  • the composition may be formulated with additives known to those skilled in the art to enhance oral absorbtion and alter bioavailability kinetics.
  • iNOS inducible nitric oxide synthase
  • the noise was digitally generated by a Tucker Davis Technologies (TDT, Alachua, FL) device and passed through a real time attenuator (TDT, RP2), filtered, amplified with a preamplifier (QSC audio power, Costa Mesa, CA), and transduced with a high frequency acoustic driver and an acoustic speaker (JBL 2350, Northridge, CA) suspended from the ceiling of the sound booth which is placed directly above the wire cages.
  • the sound spectrum output of the system was calibrated with a sound level meter centered at an octave bandwidth of 4 kHz.
  • a condenser microphone (B&K 2804, Norcross, GA) coupled to the preamplifier was placed between the two wire cages at the level of the animals' heads to monitor the noise level.
  • the noise level was continually and visually monitored using the PULSE software system [B&K Sound & Vibration Measurement (version 10.0), Norcross, GA] including FFT Analysis Type 7770 and CPB Analysis 7771.
  • ABR auditory brainstem response
  • Auditory stimuli was generated using a computer-aided system (Intelligent Hearing Systems, Miami, FL) coupled to high frequency transducers. Acoustic stimuli were tone pips (5 ms duration and 1 ms Blackman rise and fall) at frequencies of 0.5, 1, 2, 4, 6, 8, and 16 kHz. All acoustic stimuli were transduced through the computer-controlled attenuator to a 3A insert earphone [Etymotic Research (ER)-3A, Etymotic Research Inc., Elk Grove Village, IL] placed about 5 mm from the tympanic membrane, The insert earphone was calibrated with a coupler mounted to the sound level meter approximating its placement. The electrical responses obtained from the electrodes were amplifies ( ⁇ 100,000), filtered (100-3,000 Hz), and digitized through an A/D converter on a signal processing board. They were averaged at a sample rate of 1024 for each level.
  • Threshold was defined as the midpoint between the lowest level of a clear response and the next level where no response was observed.
  • the threshold shift refers to the difference in threshold prior to and following AAT. The investigators performing the ABR measurements were blinded as to the identity of the animal groups.
  • the purpose of this example is to demonstrate that 2,4-disulfonyl PBN (HPN-07) is effective to treat hearing loss induced by AAT.
  • the purpose of this example is to demonstrate the effectiveness of NAC in treating hearing loss in an animal model.
  • NAC demonstrates a mild effect on threshold shift soon after treatment
  • antioxidants such as NAC
  • the purpose of this example is to demonstrate the effectiveness of 2,4-disulfonyl PBN in combination with NAC for treating hearing loss in an animal model.
  • Figures 4A and 4B illustrate the synergistic effect of a combination treatment comprising NAC and 2,4-disulfonyl PBN.
  • Data in Figure 4A represents the average threshold shift for each individual frequency tested.
  • the data in Figure 4B represents the combined average threshold shift data from 2 kHz to 8 kHz. Data were analyzed via a two-way ANOVA, Bonferroni test "**" denotes a p value of less than 0.01 and "***" denotes a p value of less than 0.001.
  • Threshold shifts were found in the control group and treated groups at all frequencies with greater shifts in the high frequencies (2-8 kHz). See Figure 4A .
  • treatment with HPN-07 alone resulted in a significant reduction in threshold shift at 0.5, 1, 4 and 6 kHz.
  • the addition of NAC to the HPN-07 treatment composition resulted in a significant reduction in threshold shift across all frequencies tested.
  • the combined data in Figure 4B demonstrates an overall significant reduction in threshold shift when subjects were administered either HPN-07 alone or in combination with NAC.
  • Figures 4A and 4B clearly demonstrates that administration of NAC in combination with HPN-07 provides a more robust decrease in threshold shift as compared to treatment with HPN-07 alone. Taken together, these results support the use of 2,4-disulfonyl PBN and NAC in a combination therapy for treating hearing loss.
  • Figure 5A-D depicts the effects of HPN-07+NAC on hearing loss (threshold shift) as a function of time in a rat model of AAT.
  • Rats were randomly assigned to either treatment or control groups which consisted of 6 rats per time point (8h, 24h, 7d and 21d) post AAT.
  • rats were anesthetized with ketamine/xylazine and exposed for 1h to 115 dB SPL one-octave band noise centered at 14 kHz
  • HPN-07 (300 mg/kg) in combination with NAC (300 mg/kg) was administered via i.p. injection one hour after noise exposure and then administered twice a day on days 1 and 2 post AAT.
  • the hearing loss produced in the rat model was substantially greater than that observed in the chinchilla model (50-70 dB threshold shift compared to approximately 35 dB, respectively).
  • the HPN-07+NAC combination treatment was successful in significantly reducing the threshold shift as early as 24 hours post AAT (23 hours following administration of treatment).
  • HPN-07+NAC treatment resulted in significant reduction in threshold shift at all frequencies at 7 and 21 days post AAT.
  • the results in Figures 5A-D demonstrate that the combination of 2,4-disulfonyl PBN with NAC is extremely effective in reducing permanent hearing loss.
  • hearing loss resulting from AAT should begin as soon as possible.
  • treatment of other types of sensorineural hearing loss treatment using the methods and compositions described herein will vary depending on the cause of hearing loss.
  • hearing loss due to age may require delivery of one of the above described compositions on a regular treatment schedule such daily, alternating days or weekly depending on the nature of the hearing loss.
  • treatment should begin as soon as possible and will likely conclude upon restoration of hearing.
  • the current disclosure demonstrates the effectiveness of 2,4-disulfonyl PBN in treating subjects subjected to AAT.
  • the use of 2,4-disulfonyl PBN as a treatment for AAT has been shown to at least reduce hearing loss in subjects that have experienced AAT.
  • the combination of 2,4-disulfonyl PBN with NAC produces a synergistic result and further reduces hearing loss.
  • a "pharmaceutically effective amount” is an amount of a pharmaceutical compound or composition having a therapeutically relevant effect on hearing loss.
  • a therapeutically relevant effect relates to some improvement in hearing capacity or a change in the cellular, physiological or biochemical parameters associated with any of the causes of sensorineural hearing loss including but not limited to age related hearing loss or presbyacusis, toxin-induced hearing loss, trauma induced hearing loss, viral or bacterial infection leading to hearing loss, hearing loss due to prematurity, hearing loss due to cochlear ischemia, congenital hearing loss, genetic hearing loss, Meniere's disease, sudden hearing loss, and hearing loss related to thyroid disorders or diabetes mellitus.
  • 2,4-disulfonyl PBN and NAC may be administered in dosages which are pharmaceutically effective for each compound, or in dosages which are sub-clinical, i.e., less than pharmaceutically effective for each, or a combination thereof, provided that the combined dosages are pharmaceutically effective.
  • a composition comprising 2,4-disulfonyl PBN with NAC will have two parts NAC for every part of 2,4-disulfonyl PBN, i.e. a ratio of 2:1, NAC to 2,4-disulfonyl PBN.
  • concentration of NAC used in the composition of NAC with 2,4-disulfonyl PBN will be substantially less than treatment of a patient with NAC alone.
  • the compositions may comprise between about 70 mg and about 1200 mg of 2,4-disulfonyl PBN and from about 700 mg and about 4000 mg of NAC.
  • compositions comprising 2,4-disulfonyl PBN may be administered at a dose of between about 1 mg/kg to about 400 mg/kg body weight and more likely around 300 mg/kg body weight.
  • compositions comprising NAC may be administered at a dose of between about 5 mg/kg to about 300 mg/kg body weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endoscopes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (14)

  1. Zusammensetzung, umfassend eine pharmazeutisch wirksame Menge von 2,4-Disulfonyl-α-phenyl-tertiärbutylnitron oder einem Salz davon, zur Verwendung in einem Verfahren zur Behandlung sensorineuralen Gehörverlusts.
  2. Zusammensetzung zur Verwendung gemäß Anspruch 1, wobei die Zusammensetzung durch ein Verfahren abgegeben wird, ausgewählt aus der Gruppe, bestehend aus oral, intravenös, subkutan, durch Inhalation, sublingual, subdermal oder lokale Injektion innerhalb des Ohrs.
  3. Zusammensetzung zur Verwendung gemäß Anspruch 1 oder 2, wobei die Zusammensetzung weiterhin ein Antioxidans umfasst.
  4. Zusammensetzung zur Verwendung gemäß einem der voranstehenden Ansprüche, wobei die Zusammensetzung ferner ein oder mehr Verbindungen umfasst, ausgewählt aus der Gruppe, bestehend aus: N-Acetylcystein, Acetyl-L-carnitin, Glutathionmonoethylester, Ebselen, D-Methionin, Carbamathion und Szeto-Schiller-Peptiden.
  5. Zusammensetzung zur Verwendung gemäß Anspruch 4, wobei die Zusammensetzung zumindest N-Acetylcystein enthält.
  6. Zusammensetzung zur Verwendung gemäß einem der voranstehenden Ansprüche, wobei die Zusammensetzung anfänglich innerhalb von vier Stunden eines akuten akustischen Traumaereignisses verabreicht wird.
  7. Zusammensetzung zur Verwendung gemäß einem der voranstehenden Ansprüche, wobei die Zusammensetzung mindestens zweimal innerhalb von 24 Stunden eines akuten akustischen Traumaereignisses abgegeben wird.
  8. Zusammensetzung zur Verwendung gemäß einem der voranstehenden Ansprüche, wobei die Zusammensetzung 1 mg/kg bis 400 mg/kg Organismuskörpergewicht 2,4-Disulfonyl-α-phenyltertiärbutylnitron, oder ein Salz davon, umfasst.
  9. Zusammensetzung zur Verwendung gemäß Anspruch 5, wobei die Zusammensetzung 1 mg/kg bis 400 mg/kg Organismuskörpergewicht 2,4-Disulfonyl-α-phenyltertiärbutylnitron, oder ein Salz davon, und 5 mg/kg bis 300 mg/kg Organismuskörpergewicht N-Acetylcystein umfasst.
  10. Zusammensetzung, geeignet zur Behandlung von sensorineuralem Gehörverlust, umfassend:
    eine erste Komponente, umfassend eine pharmazeutisch wirksame Menge von 2,4-Disulfonyl-α-phenyltertiärbutylnitron oder einem Salz davon, und
    eine zweite Komponente, umfassend eine pharmazeutisch wirksame Menge von einer oder mehreren Verbindungen, ausgewählt aus der Gruppe, bestehend aus: N-Acetylcystein, Acetyl-L-carnitin, Glutathionmonoethylester, Ebselen, D-Methionin, Carbamathion und Szeto-Schiller-Peptiden.
  11. Zusammensetzung gemäß Anspruch 10, wobei die zweite Komponente zumindest N-Acetylcystein ist.
  12. Zusammensetzung gemäß Anspruch 10, umfassend 2,4-Disulfonyl-α-phenyltertiärbutylnitron, oder ein Salz davon, und N-Acetylcystein.
  13. Zusammensetzung gemäß Anspruch 12, wobei die Zusammensetzung 70 mg bis 1.200 mg 2,4-Disulfonyl-α-phenyltertiärbutylnitron, oder ein Salz davon, und 700 mg bis 4.000 mg N-Acetylcystein enthält.
  14. Zusammensetzung gemäß Anspruch 13, wobei die Zusammensetzung ferner 70 mg bis 1.200 mg Acetyl-L-carnitin umfasst.
EP10814226.6A 2009-08-24 2010-08-24 Nitrone derivate zur behandlung von schallempfindungsschwerhörigkeit Active EP2470015B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27411809P 2009-08-24 2009-08-24
PCT/US2010/046420 WO2011028503A1 (en) 2009-08-24 2010-08-24 Methods for treating acute acoustic trauma

Publications (3)

Publication Number Publication Date
EP2470015A1 EP2470015A1 (de) 2012-07-04
EP2470015A4 EP2470015A4 (de) 2013-01-09
EP2470015B1 true EP2470015B1 (de) 2016-01-13

Family

ID=43649578

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10814226.6A Active EP2470015B1 (de) 2009-08-24 2010-08-24 Nitrone derivate zur behandlung von schallempfindungsschwerhörigkeit

Country Status (8)

Country Link
US (2) US10555915B2 (de)
EP (1) EP2470015B1 (de)
JP (2) JP5762414B2 (de)
AU (1) AU2010289838C1 (de)
CA (1) CA2772097C (de)
ES (1) ES2563777T3 (de)
IL (1) IL218302A (de)
WO (1) WO2011028503A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131981A1 (en) * 2015-02-20 2016-08-25 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
WO2017048778A1 (en) * 2015-09-18 2017-03-23 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
TWI642431B (zh) * 2016-10-28 2018-12-01 西德有機化學藥品股份有限公司 Ｎ－乙醯半胱胺酸用於治療突發性感覺神經性聽力損失的方法
EP3532042A4 (de) * 2016-10-31 2020-06-24 Hough Ear Institute Verfahren zur verbesserung der synaptogenese und neuritogenese
KR20190119046A (ko) * 2017-01-19 2019-10-21 오톨로직 파마슈틱스, 인크. N-아세틸시스테인의 제제 및 이의 용도
JP6999896B2 (ja) 2017-09-21 2022-01-19 学校法人慶應義塾 音響外傷難聴モデル動物の作製方法及びそれにより作製される音響外傷難聴モデル動物
WO2019213245A1 (en) * 2018-05-03 2019-11-07 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
WO2020056056A1 (en) * 2018-09-12 2020-03-19 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
EP4309655A1 (de) * 2022-07-22 2024-01-24 Consejo Superior de Investigaciones Científicas (CSIC) Chinolylnitronderivate zur verwendung bei der vorbeugung und/oder behandlung von hörverlust

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6469049B1 (en) 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
SE0001916D0 (sv) 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US20030191064A1 (en) * 2001-01-23 2003-10-09 Kopke Richard D. Methods for preventing and treating loss of balance function due to oxidative stress
US7700111B2 (en) 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth
US20050054646A1 (en) 2003-06-09 2005-03-10 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
EP2005951A2 (de) 2006-03-29 2008-12-24 Kaneka Corporation Mittel zur verbesserung der nervensystem-zellfunktionen
US8420595B2 (en) * 2006-07-25 2013-04-16 Oklahoma Medical Research Foundation Methods for treating acute acoustic trauma
CA2661012C (en) * 2006-08-29 2019-03-19 Genentech, Inc. Method of treating stroke with thrombolytic agent
US20100234402A1 (en) * 2007-05-31 2010-09-16 Gideon Dreyfuss Methods and compositions for treating spinal muscular atrophy
KR20210107137A (ko) 2008-04-21 2021-08-31 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US20140302322A1 (en) 2011-09-06 2014-10-09 Ricardo Prada Silvy Single wall carbon nanotube purification process and improved single wall carbon nanotubes

Also Published As

Publication number Publication date
IL218302A0 (en) 2012-04-30
CA2772097C (en) 2019-04-30
AU2010289838B2 (en) 2013-11-07
JP2015172071A (ja) 2015-10-01
JP2013502461A (ja) 2013-01-24
US10555915B2 (en) 2020-02-11
JP5762414B2 (ja) 2015-08-12
EP2470015A1 (de) 2012-07-04
US20120172435A1 (en) 2012-07-05
WO2011028503A1 (en) 2011-03-10
ES2563777T3 (es) 2016-03-16
IL218302A (en) 2017-02-28
AU2010289838C1 (en) 2014-03-06
CA2772097A1 (en) 2011-03-10
EP2470015A4 (de) 2013-01-09
AU2010289838A1 (en) 2012-04-19
JP6038233B2 (ja) 2016-12-07
US20170224635A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
EP2470015B1 (de) Nitrone derivate zur behandlung von schallempfindungsschwerhörigkeit
JP5236641B2 (ja) 急性音響外傷の治療方法
EP2872128B1 (de) Nicotinamidribosid zur behandlung von gehörverlust
JP2009510047A (ja) 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法
US8053424B2 (en) Composition and method of treating hearing loss
Tamir et al. Uniform comparison of several drugs which provide protection from noise induced hearing loss
Pouyatos et al. Acrylonitrile potentiates hearing loss and cochlear damage induced by moderate noise exposure in rats
US20070105782A1 (en) Protectant Combinations for Reducing Toxicities
Muthaiah et al. Effect of manganese and manganese plus noise on auditory function and cochlear structures
Pouyatos et al. Lipoic acid and 6-formylpterin reduce potentiation of noise-induced hearing loss by carbon monoxide: preliminary investigation.
AU2016393202B2 (en) Treatment of tinnitus using glutamate receptor agonists
US9763992B2 (en) Treatment of noise induced hearing loss
Wolters et al. Perilymphatic application of α-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin
JP2004510737A (ja) 薬剤の使用
CA2733918A1 (en) The treatment of hearing loss

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120322

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121207

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/16 20060101ALI20121203BHEP

Ipc: A01N 43/42 20060101AFI20121203BHEP

Ipc: A61K 31/44 20060101ALI20121203BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150710

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 769866

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010030233

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2563777

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160316

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160113

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 769866

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160414

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160513

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160513

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010030233

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

26N No opposition filed

Effective date: 20161014

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20200828

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210824

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230830

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230830

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240226

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240226

Year of fee payment: 14

Ref country code: FR

Payment date: 20240226

Year of fee payment: 14